Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2010 1
2011 3
2012 1
2014 1
2016 1
2018 1
2020 2
2021 1
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases.
Strassheim D, Verin A, Batori R, Nijmeh H, Burns N, Kovacs-Kasa A, Umapathy NS, Kotamarthi J, Gokhale YS, Karoor V, Stenmark KR, Gerasimovskaya E. Strassheim D, et al. Among authors: nijmeh h. Int J Mol Sci. 2020 Sep 18;21(18):6855. doi: 10.3390/ijms21186855. Int J Mol Sci. 2020. PMID: 32962005 Free PMC article. Review.
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Tyler LC, Le AT, Chen N, Nijmeh H, Bao L, Wilson TR, Chen D, Simmons B, Turner KM, Perusse D, Kasibhatla S, Christiansen J, Dudek AZ, Doebele RC. Tyler LC, et al. Among authors: nijmeh h. Thorac Cancer. 2022 Nov;13(21):3032-3041. doi: 10.1111/1759-7714.14656. Epub 2022 Sep 13. Thorac Cancer. 2022. PMID: 36101520 Free PMC article.
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway.
Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, Davies KD, Lawrence C, O'Donnell E, Doebele RC, Bao L, Aisner DL, Schenk EL. Priest K, et al. Among authors: nijmeh h. NPJ Precis Oncol. 2023 Jan 23;7(1):9. doi: 10.1038/s41698-023-00349-0. NPJ Precis Oncol. 2023. PMID: 36690705 Free PMC article.
PDGFB:APOBEC3C fusion in congenital diffuse high-grade glioma of the brainstem.
Norris GA, Willard N, Donson AM, Gaskell A, Milgrom SA, O'Neill BR, Nijmeh H, Haag M, Gilani A, Foreman NK, Dahl NA. Norris GA, et al. Among authors: nijmeh h. J Neuropathol Exp Neurol. 2023 Jan 20;82(2):183-186. doi: 10.1093/jnen/nlac112. J Neuropathol Exp Neurol. 2023. PMID: 36440550 Free PMC article. No abstract available.
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica JM, Koehler K, Cass A, Kuykendall H, Schmitt E, Filar E, Reventaite E, Davies KD, Nijmeh H, Haag M, Yoder BA, Bunn PA, Schenk EL, Aisner DL, Iams WT, Marmarelis ME, Camidge DR. Patil T, et al. Among authors: nijmeh h. JTO Clin Res Rep. 2024 Jan 18;5(2):100637. doi: 10.1016/j.jtocrr.2024.100637. eCollection 2024 Feb. JTO Clin Res Rep. 2024. PMID: 38361741 Free PMC article.
Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
Tsui DCC, Aisner D, Nijmeh H, Bao L, Menter A, Camidge DR. Tsui DCC, et al. Among authors: nijmeh h. Clin Lung Cancer. 2022 Mar;23(2):e99-e103. doi: 10.1016/j.cllc.2021.06.012. Epub 2021 Jul 3. Clin Lung Cancer. 2022. PMID: 34330640 No abstract available.
16 results